Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy.

Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges. Copyright © 2024 Elsevier Inc. All rights reserved.

Citation

Robin Demuynck, Yanou Engelen, André G Skirtach, Stefaan C De Smedt, Ine Lentacker, Dmitri V Krysko. Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy. Trends in cancer. 2024 Jun;10(6):486-489

Mesh Tags

Substances

PMID: 38553361

search → result